APA (7th ed.) Citation

Wang, P., Ahmed, M. S., Nguyen, N. U. N., Menendez-Montes, I., Hsu, C., Farag, A. B., . . . Sadek, H. A. (2025). An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models. The Journal of clinical investigation, 135(4), . https://doi.org/10.1172/JCI174081

Chicago Style (17th ed.) Citation

Wang, Ping, et al. "An FDA-approved Drug Structurally and Phenotypically Corrects the K210del Mutation in Genetic Cardiomyopathy Models." The Journal of Clinical Investigation 135, no. 4 (2025). https://doi.org/10.1172/JCI174081.

MLA (9th ed.) Citation

Wang, Ping, et al. "An FDA-approved Drug Structurally and Phenotypically Corrects the K210del Mutation in Genetic Cardiomyopathy Models." The Journal of Clinical Investigation, vol. 135, no. 4, 2025, https://doi.org/10.1172/JCI174081.